Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2002, for Anthem, Inc. (now Elevance Health). The company is a major health benefits provider and an independent licensee of the Blue Cross Blue Shield Association. The reporting period is significantly impacted by the completion of the acquisition of Trigon Healthcare, Inc. on July 31, 2002, which established a new Southeast segment. The company also completed its demutualization and initial public offering in November 2001.
Key Financial Metrics
| Metric (Nine Months Ended Sept 30, 2002) | Value ($ Millions) | Prior Year (2001) |
|---|---|---|
| Total Operating Revenue | $9,090.2 | $7,525.9 |
| Net Income | $377.2 | $254.5 |
| Net Income Per Share (Diluted) | $3.30 | $2.45 |
| Operating Gain | $418.7 | $212.4 |
| Benefit Expense Ratio | 83.1% | 85.2% |
| Operating Margin | 4.6% | 2.8% |
| Total Assets | $12,235.2 | $6,276.6 |
| Total Liabilities | $6,909.9 | $4,216.6 |
| Long-Term Debt | $1,658.5 | $818.0 |
| Cash and Cash Equivalents | $912.0 | $406.4 |
| Net Cash Provided by Operating Activities | $623.9 | $511.8 |
Material Changes vs. Prior Period
- Revenue Growth: Total operating revenue increased 21% year-over-year, driven primarily by the Trigon acquisition and organic growth in premiums and administrative fees.
- Profitability: Net income rose 48% to $377.2 million. Operating gain increased 97% to $418.7 million, reflecting improved underwriting results and the inclusion of Trigon's operations.
- Balance Sheet Expansion: Total assets nearly doubled to $12.2 billion due to the acquisition. Goodwill increased significantly to $2,502.3 million, and long-term debt rose to $1,658.5 million to fund the Trigon purchase.
- Membership: Total membership reached 10.95 million, a 40% increase. Excluding the Trigon acquisition, same-store membership grew 7%.
- Investment Income: Net realized gains on investments decreased significantly (from $61.2M to $13.2M) due to a lack of large equity sales compared to the prior year's portfolio restructuring.
Guidance, Outlook, and Risks
Management Commentary: Management attributes improved results to better-than-expected claims experience, favorable reserve developments, and the successful integration of Trigon. The company implemented three-tier drug programs to manage pharmacy costs, which rose 17% year-over-year. The effective tax rate decreased to 29.5% for the nine-month period due to a reduction in deferred tax valuation allowances.
Outlook and Pending Transactions: The company is pursuing the acquisition of Blue Cross and Blue Shield of Kansas (BCBS-KS). While a court vacated the Kansas Insurance Commissioner's disapproval, the matter is currently under appeal to the Kansas Supreme Court. The company expects to fund future acquisitions through cash from operations, investment portfolios, or new borrowings.
Risks and Contingencies:
- Litigation: The company faces multiple class-action lawsuits regarding provider reimbursement practices (e.g., "down-coding" claims), ERISA violations, and antitrust allegations in Ohio and Kentucky. A significant wrongful death case in Ohio is pending before the Supreme Court of Ohio regarding punitive damages.
- Regulatory: Ongoing federal reviews of Medicare fiscal intermediary operations and the Federal Employee Program (FEP) could result in fines or penalties, though management does not expect a material adverse effect.
- Market Risk: The company is exposed to interest rate risk, credit risk, and market valuation risk regarding its investment portfolio, which represents 46% of total assets.
Investor Verification Checklist
- Trigon Integration: Verify the realization of expected synergies and operating efficiencies from the Trigon acquisition, which added $2.1 billion in goodwill.
- Claims Reserves: Monitor the stability of the liability for unpaid claims ($1.9 billion), as adjustments for reserve developments significantly impacted earnings in both 2001 and 2002.
- BCBS-KS Acquisition: Track the outcome of the Kansas Supreme Court appeal regarding the proposed $190 million acquisition of BCBS-KS.
- Pharmacy Cost Trends: Assess the effectiveness of three-tier drug programs in curbing the 17% increase in pharmacy costs.
- Legal Exposure: Review the status of the Ohio wrongful death appeal and the Multi-District Litigation (MDL) regarding provider reimbursement practices.